中国医学创新2024，Vol.21Issue(33)：66-70,5.DOI:10.3969/j.issn.1674-4985.2024.33.016
舒格利单抗联合GP方案对非小细胞肺癌患者细胞生长因子及肿瘤标志物的影响
Effects of Sugemalimab Combined with GP Regimen on Cell Growth Factors and Tumor Markers in Patients with Non-small Cell Lung Cancer
摘要
Abstract
Objective:To observe the effects of Sugemalimab combined with Gemcitabine+Cisplatin(GP)regimen on the expression of cell growth factors and tumor markers in patients with non-small cell lung cancer(NSCLC),in order to provide scientific reference for the new treatment regimen for clinical NSCLC patients.Method:A total of 80 patients with NSCLC admitted to Ganxian District People's Hospital of Ganzhou City from May 2022 to May 2023 were divided into control group and study group by random number table method,with 40 cases in each group.The control group received GP regimen,and the study group received GP regimen combined with Sugemalimab.The short-term effect,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCCA),cytokeratin 19 fragment(Cyfra21-1)]and cell growth factors[vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF)]and the occurrence of adverse reactions were compared between the two groups.Result:The objective remission rate of the study group was higher than that of the control group,the difference was statistically significant(P<0.05).There was no significant difference in disease control rate between the two groups(P>0.05).Before treatment,there were no significant differences in CEA,CA125,SCCA,Cyfra21-1,VEGF and bFGF between the two groups(P>0.05).After treatment,CEA,CA125,SCCA,Cyfra21-1,VEGF and bFGF in study group were lower than those in control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of total adverse reactions between the two groups(P>0.05).Conclusion:Compared with GP regimen alone,Sugemalimab combined with GP regimen can improve the short-term effect of patients with NSCLC,improve the expression of tumor markers and cell growth factors,and have good safety.关键词
非小细胞肺癌/舒格利单抗/肿瘤标志物/细胞生长因子Key words
Non-small cell lung cancer/Sugemalimab/Tumor markers/Cell growth factors引用本文复制引用
龙腾飞..舒格利单抗联合GP方案对非小细胞肺癌患者细胞生长因子及肿瘤标志物的影响[J].中国医学创新,2024,21(33):66-70,5.基金项目
2023年赣州市指导性科技计划项目(GZ2023ZSF362) （GZ2023ZSF362）
